The link between cholesterol homeostasis and the cleavage of the amyloid precursor protein (APP), and their relationship to the pathogenesis of Alzheimer's disease (AD) is still unknown. Cellular cholesterol levels are regulated by a crosstalk between the plasma membrane (PM), where most of the cholesterol resides, and the endoplasmic reticulum (ER), where the protein machinery that regulates cholesterol resides. This crosstalk between PM and ER is believed to be regulated by lipid-sensing peptide(s) that can modulate the internalization of extracellular cholesterol and/or its de novo synthesis in the ER. Our data here indicates that the 99-aa C-terminal fragment of APP (C99), a cholesterolbinding peptide, regulates cholesterol trafficking between the PM and the ER. In AD models, increases in C99 provoke the upregulation of cholesterol internalization and its delivery to the ER, which in turn result into the loss of lipid homeostasis and the appearance of AD signatures, such as higher production of longer forms of amyloid b. Our data suggest a novel role of C99 as mediator of cholesterol disturbances in AD, and as a potential early hallmark of the disease.
is activated by the transport of the sterol regulatory element binding protein isoform 2 (SREBP2) from the ER to the Golgi, and its subsequent activation by proteolytic cleavage (6) . The processed form of SREBP2 translocates to the nucleus and induces the transcription of cholesterolsynthesizing genes, as well as of the SREBP2 gene itself (6) . When cholesterol supply is sufficient, SREBP2 is retained in the ER in its uncleaved form, thereby pre-empting the de novo synthesis pathway. (6) .
When taken up from lipoproteins, the internalized CEs are hydrolyzed in endolysosomes to unesterified-free cholesterol, most of which is transferred to the PM (7, 8) . Once PM cholesterol surpasses a threshold, it is transported to the ER for esterification by the enzyme acyl-coenzyme A:cholesterol acyl-transferase 1 (ACAT1), as a means to detoxify the excess of cholesterol (7) .
The resultant CEs are stored in lipid droplets in the cytosol before being secreted (7) .
Thus, to preserve cholesterol homeostasis, the cell maintains a crosstalk between the PM, where the bulk of cholesterol resides, and the ER, where the enzymatic activities that ensure cholesterol levels reside (9) . This crosstalk is believed to be controlled by an as-yet-unknown sensor in the ER that triggers the communication between the PM and the intracellular ER regulatory pool of cholesterol where ACAT1 resides, or MAM (8, 10) .
The regulation of lipid metabolism is particularly critical within the nervous system (11) . It is therefore not surprising that lipid deregulation has been described numerous times in neurodegenerative diseases, including Alzheimer's disease (AD) (12) . Specifically, cholesterol anomalies in AD have been widely reported (12) , but the field currently lacks consensus as to their cause(s).
The "amyloid cascade hypothesis" in AD pathogenesis states that increases in the levels of β-amyloid peptide (Aβ), derived from APP processing, trigger neurodegeneration (13) . These higher levels of Aβ in AD are the consequence of corresponding increases in the cleavage of endocytosed full-length APP by β-secretase to produce the immediate precursor of Aβ, the 99-aa C-terminal domain of APP (C99), and its subsequent processing by g-secretase (13) . These alterations in APP metabolism are due to mutations in the PSEN1 [presenilin-1 (PS1)], PSEN2
[presenilin-2 (PS2)], and APP genes in familial AD (FAD), or by unknown causes in sporadic cases (SAD) (13) . Further linking AD and cholesterol, APP-CTFs processing occurs in lipid rafts (14) . Notably, elevations in C99 have been shown to contribute to AD (15) causing endosomal dysfunction (16) , and hippocampal degeneration (17) .
Previously, we and others found that C99, when delivered to the ER for cleavage by gsecretase, is not distributed in the ER homogeneously, but concentrated at mitochondriaassociated ER membranes (MAMs) (18) (19) (20) . MAM is a lipid raft in the ER (21, 22) , involved in the regulation of lipid homeostasis (23) . We showed that in AD cell and animal models, there is an increased of C99 at MAM (20) , resulting in the upregulation of MAM activities (22, 24) , including SMases, and cholesterol esterification by ACAT1 (20) . Remarkably, inhibition of C99 production caused the inactivation of these MAM functions (20) .
We now report that, by means of its affinity for cholesterol (25) , the pathogenic buildup of C99 in the ER (20) induces the uptake of extracellular cholesterol and its trafficking from the PM towards the ER, resulting in the persistent formation, activation and turnover of MAM domains.
Altogether, our data suggest a pathogenic role for elevations in C99 via upregulation of cholesterol trafficking and MAM activity, which in turn abrogate cellular lipid homeostasis and disrupt the lipid composition of cellular membranes.
RESULTS

Deficiency in g-secretase activity triggers cellular cholesterol uptake and trafficking to MAM
Co-activation of SMase(s) and ACAT1 is a mechanism by which cells "detoxify" membranes from an excess of cholesterol (10) . Therefore, we hypothesized that the upregulation of sphingolipid turnover and of cholesterol esterification caused by increases in uncleaved C99 (20) , could be the consequence of the activation of this detoxifying mechanism, provoked by elevations in cholesterol in cell membranes.
To test this, we measured the concentration of cholesterol in membranes and subcellular fractions from mouse embryonic fibroblasts (MEFs) null for both PSEN1 and PSEN2 (PS-DKO) (26) ( Fig. 1A ) and from homogenates from AD fibroblasts (Fig. S1A ) by liquid chromatographymass spectrometry (LC-MS) (27) , and found that they displayed increased levels of free cholesterol when compared to controls (Fig. 1A) . This increase in membrane-bound cholesterol was highly significant in ER and MAM membranes, which, in light of previous data (22) , suggests that the upregulation of cholesterol esterification in AD cell models is the result of cholesterol buildup in membranes and subsequent elimination by esterification. We were able to recapitulate this increase in free cholesterol levels in MEFs in which both APP and its paralog APLP2 were knocked out (APP-DKO) (28) , transiently transfected with a plasmid expressing C99, compared to controls (Fig. 1B) . Conversely, APP-DKO cells expressing either the APP-C83 peptide (produced by the cleavage of APP by a-secretase) or incubated with amyloid oligomers did not show these cholesterol elevations, suggesting that C99, and no other APP fragment, affected cholesterol homeostasis (Fig. 1B) .
To determine whether cholesterol increases in AD cells occurred via upregulation of the de novo cholesterol synthesis, we quantified the activity of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme in the synthesis of cholesterol, in g-secretasedeficient cells and in controls. HMGCR activity was reduced significantly in PS-DKO MEFs, in cells treated with g-secretase inhibitors (DAPT) (Fig. 1C) , and in AD fibroblasts (Fig. S1B ), in agreement with previous observations (29) . Consistently, total levels of SREBP2 were significantly lower in the PS-DKO cells, as was that of mature SREPB2 after DAPT treatment Given this reduced de novo synthesis of cholesterol, we then measured the rate of uptake of extracellular cholesterol in PS-DKO cells and controls, by incubating them with 3 H-cholesterol and following its internalization over time. Mutant cells showed an enhanced rate of cholesterol uptake compared to controls, whereas treatment of these cells with a BACE1 inhibitor had the opposite effect ( Fig. 1D ). We also observed increased cholesterol uptake in neuronal cells silenced for PS1 alone or for both PS1+PS2 (Fig. S1D) , and in AD fibroblasts (Fig. S1E ).
Supporting this result, the uptake of fluorescently-labeled cholesterol was also increased in PS-DKO cells compared to controls ( Fig. 1E-F) . Interestingly, this increase in either radioactive Staining of our cells with filipin, a dye that binds to free cholesterol, showed that the distribution of free cholesterol was also markedly different in PS-DKO mutant ( Fig. 1G-H) , and in AD fibroblasts vs. controls (Fig. S1F) , which showed a higher degree of cholesterol punctae in the cytosol, suggesting an increased rate of cholesterol influx into mutant cells.
To address the subcellular destination of the internalized cholesterol, we tracked the uptake of 3 H-cholesterol, and its delivery to MAM and bulk ER by pulse-chase analysis and subcellular fractionation. We found that in PS-DKO cells the rate of cholesterol incorporation into MAM was higher when compared to controls, and was abrogated upon BACE1 inhibition ( Fig. 1I-J) . We were able to recapitulate this phenotype (Fig. S1G-H) in iPSCs in which a pathogenic mutation in APP (London mutation; APP V717I ) was knocked into both alleles using CRISPR/Cas9, which showed higher levels of C99 relative to isogenic control iPSCs (Fig. S1J ). This enhanced trafficking of cholesterol from the PM to the ER-MAM was also reflected in an increased ratio of cholesteryl esters: free cholesterol (CE:FC) (8, 30) in PS-DKO cells (Fig. 1K ), in our cell models expressing mutant APP V717I (Fig. S1I) , and in cells from AD patients (Fig. S1K) .
In cellular membranes, a pool of cholesterol in the PM is complexed with SM, preventing its mobilization (7, 31) , although treatment with SMases can release the membrane-bound cholesterol and induce its transport to the ER (30) . Our previous data revealed that increases in MAM-localized C99 trigger the upregulation of SMase(s) activity (20) . Thus, we asked whether the increases in cholesterol trafficking towards ER-MAM domains were a consequence of sustained SMase activity provoked by increases in MAM-C99.
To test this, we treated our cells with SMase inhibitors, and then stained them with filipin or LipidTox Green, a dye that visualizes lipid droplets (LDs). As before (20) , incubation with the SMase(s) inhibitors reduced cholesterol esterification by ACAT1 and the accumulation of LDs in PS-DKO cells ( Fig. 2A-B) , in DAPT-treated SH-SY5Y cells and AD patient fibroblasts (Fig. S2) .
Thus, the increase in ACAT1 activity and in LD production associated with elevated C99 was facilitated by activation of SMase(s), consistent with previous findings (30) . However, cholesterol uptake was not reversed by SMase inhibition in either DAPT-treated WT cells ( Fig. 2C-D) , or in PS-DKO cells ( Fig. 2E-F) , thereby indicating that SMase upregulation is likely not a cause, but rather a consequence, of a prior enrichment of cholesterol in membranes.
Taken together, our results suggest that g-secretase-deficient cells suffer from an excessive internalization of cholesterol and delivery to MAM, where its esterification by ACAT1 is facilitated by SM hydrolysis by SMase(s) (20) . Our data also indicate that this mobilization of cholesterol to ER-MAM has the further effect of reducing de novo cholesterol biosynthesis via inactivation of SREBP2.
Localization of C99 at MAM depends on its cholesterol binding domain.
The C99 APP fragment contains a cholesterol binding motif within its transmembrane domain (25) , that could promote its localization to lipid rafts (32) , such as MAM (20, 22) . To test whether C99's cholesterol binding domain (CBD) was necessary for its localization to MAM, we transfected APP-DKO cells with plasmids expressing WT C99 and a mutant C99 construct with reduced affinity for cholesterol (G700AII703G704 was mutated to A700AIA703A704; named C99 CBD for simplicity), and treated them with DAPT to impede C99 cleavage before analyzing its subcellular localization To gain insight into these changes in C99 localization, we run membrane homogenates from these same transfected cells through a continuous density sucrose gradient, and analyzed the migration of specific markers by western blot (Fig. 3B) . As shown before (20) , C99 WT comigrated with endosomal (Rab5) and MAM markers (Acsl4) ( Fig 3C) . However, C99 CBD showed reduced comigration with MAM markers (Fig. 3D) . As expected, flotillin, a protein with affinity for cholesterol, also comigrated with MAM markers in cells transfected with C99 WT (Fig. 3E) .
Conversely, in the presence of C99 CBD , flotillin showed a reduced comigration with MAM proteins (Fig. 3F ), suggesting that C99 binding to cholesterol not only is important for its localization to MAM, but for the proper formation of MAM itself.
As a lipid raft, MAM (22) , is a transient functional domain formed by local increases in cholesterol mediated by peptides with CBD capable of docking cholesterol until it coalesces into a rigid domain (3) . Thus, in light of our results, we hypothesized that C99, when delivered to the ER, docks to cholesterol via its CBD, thereby helping form MAM domains. To test this, we decided to analyze C99 affinity for cholesterol using a PhotoClick-cholesterol chemistry approach (Fig.   4A ), a photoreactive alkyne cholesterol analog that faithfully mimics native cholesterol, and that can serve as a tool to determine protein affinity for cholesterol (33) . We incubated APP-DKO cells transiently expressing C99 WT or C99 CBD with this trans-sterol probe. Subcellular fractions from these cell models were then conjugated to an azide-biotin tag by click chemistry, followed by a pull-down assay using streptavidin beads (Figs. 4A and S4A-B) . As a proof of principle, we were able to detect increased levels of C99 WT bound to cholesterol in MAM fractions from PS-DKO cells (Fig. S4C) .
The levels of click-cholesterol in homogenates of APP-DKO cells expressing C99 WT or C99 CBD were comparable (Fig. 4B-C) . However, pull-down of the added PhotoClick-cholesterol revealed that the amount of C99 CBD bound to this lipid was significantly reduced when compared to that of C99 WT (Fig. 4B-C) , demonstrating that, as reported (25) , the C99 residues G700AII703G704 are pivotal for C99 cholesterol binding.
Moreover, cells transfected with C99 CBD exhibited significant reductions in the amount of clickcholesterol that was transferred to MAM (Fig. 4B) . Consistently, lipidomics analysis showed reductions in cholesterol in MAM fractions from C99 CBD vs C99 WT cells (Fig. S4D) . Similar to the results obtained in homogenates, pull-down of the click cholesterol present in MAM fractions from cells transfected with C99 CBD displayed lower levels of bound C99 (Fig. 4B-C-D) .
Taken together, our results support the idea that the cholesterol binding domain of C99 is necessary to induce cholesterol internalization for the formation of MAM in the ER (34) . In support of this conclusion, the apposition between ER and mitochondria was significantly decreased in APP-DKO cells expressing C99 CBD when compared to controls (Fig. 5A-B) .
We measured MAM activity in APP-DKO cells expressing either C99 WT or C99 CBD vs. controls by analyzing the synthesis and transfer of phospholipids between ER and mitochondria (23) . As shown before (20) , overexpression of C99 WT resulted in significant increases in the crosstalk between ER and mitochondria ( Fig. 5C-E) . Conversely, expression of C99 CBD showed significantly lower effects on MAM activity, thus corroborating the importance of C99 cholesterol binding on MAM activation. Consistently, C99 WT expression in the presence of DAPT resulted in the upregulation of SMase activity (Fig. 5F) , and of cholesterol esterification by ACAT1 (Fig. 5G) ,
whereas expression of C99 CBD did not show any difference when compared to controls. In agreement with these data, APP-DKO expressing C99 WT showed significant increases in LDs ( Fig. S5A-B) , and a higher ratio of CE:FC (30) (10) when compared to its C99 CBD counterpart and controls (Fig. S5C) .
Altogether, our results suggest that C99 capacity to recruit and cluster cholesterol in the ER triggers the formation and activation of MAM domains. Moreover, the increased concentration of uncleaved C99 fragments in the ER in cells from AD patients induces the constant turnover of MAM domains by activating the entry of cholesterol and its trafficking to MAM (Fig. 6 ).
DISCUSSION
In previous reports, we and others have found that, g-secretase activity is localized in the ER, although not homogeneously; rather it is enriched in MAM domains (18, 19) . Moreover, alterations in g-secretase activity result in the functional upregulation of this ER region and in increased ER-mitochondria apposition (22, 24) .
Recently, we showed that the g-secretase substrate, C99, is also enriched in MAM and that, alterations in g-secretase activity provoke an accumulation of this APP fragment in MAM membranes that in turn, cause the upregulation of MAM activities, increased cholesterol esterification and sphingolipid turnover, and mitochondrial dysfunction (20) . We now show that these phenotypes are consequences of the continuous uptake of extracellular cholesterol and its delivery to the ER, provoked by increased levels of C99.
Our data supports a model ( Fig. 6) in which C99 at MAM, induces the uptake and transport of cholesterol from the PM to the ER (9), via an as-yet unknown mechanism, which results in the inhibition of the SREBP2-regulated pathway(s) (6) . We propose that, under normal circumstances ( Fig. 6, upper panel) , C99, via its CBD, causes cholesterol to cluster in the ER, resulting in the formation of MAM domains. As this MAM-cholesterol pool expands in, it will activate the hydrolysis of sphingomyelin by SMases, exposing cholesterol to ACAT1 for esterification, which will decrease the concentration of membrane-bound cholesterol, resulting in the dissolution of the lipid raft (4) . In this way, C99 promotes a self-regulating feedback loop to help maintain intracellular cholesterol levels.
Under this point of view, the failure to cleave C99 (35) (Fig. 6, lower panel) , would result in a futile cycle of continuous uptake of cholesterol and its mobilization from the PM to ER, resulting in the upregulation of MAM formation and activation, which in turn would cause the upregulation of SMases, ACAT1 activity, and LD deposition. Closing the cycle, this accumulation of cholesterol in the PM would also induce APP internalization and its interaction with, and cleavage by, BACE1 (36) , and the downregulation of α-secretase activity (37) . Interestingly, increases in exogenous cholesterol can mimic this scenario, resulting in APP internalization and C99 elevations (38) , increases in the Ab42:40 ratio (39), Tau phosphorylation (40) , and hippocampal atrophy and cognitive impairment (41) .
Our results are thus in support of a pathogenic role for C99 in AD. In the AD brain, there is a substantial increase in the production of amyloid, which originates from high levels of C99 fragments (17) . Thus, the buildup of C99 in AD could be considered an early pathological hallmark that may elicit many of the molecular symptoms of the disease, including endosomal dysfunction (16) , cognitive impairment, and hippocampal degeneration (17) . Interestingly, others have found that changes in C99, rather than Aβ or AICD, could be behind some of the symptoms of dementia (42) . In light of these reports and our own data, we believe that C99 toxicity in AD is mediated by its role on cholesterol metabolism.
Consistent with previous data (29) , our results show that the buildup of C99 in MAM correlates with significant decreases in HMGCR and SREBP2 and the de novo synthesis of cholesterol, in an Aβ-and AICD-independent fashion. Thus, while the specific pathway needs to be elucidated, these data suggest that the accumulation of C99 prevents SREBP2 activation, impeding its function as a transcriptional factor (6) . We note that one of the SREBP2-regulated genes is the LDL receptor, whose expression would also be reduced by SREBP2 downregulation in a feedback mechanism to control cholesterol levels (6) . Paradoxically, our results also reveal that cholesterol uptake is highly induced in g-secretase deficient cells. The intriguing failure of this negative feedback mechanism, suggests that this continuous cholesterol uptake might occur through one of the SREBP2-independent cholesterol receptors expressed in the cell (43) .
As mentioned above, when in excess, a pool of "active" cholesterol in the PM will be proportionally transported to the ER cholesterol pool, where it will trigger feedback responses to maintain homeostasis (7) (8) (9) . It has been suggested that this trafficking is regulated by cholesterolsensing proteins and/or a specific cholesterol-sensing membrane domain in the ER associated with ACAT1 (10) . Based on previous studies (44) and the results presented here, we propose that C99, via its CBD (25) , acts as a cholesterol sensing protein, and that the MAM acts as signaling platform in the regulation of cholesterol homeostasis. Thus, it is possible that via this affinity domain, the accumulation of C99 generates cholesterol-rich areas needed for its cleavage by the γ-secretase complex. Hence, in the context of a deficient γ-secretase activity, uncut C99 will continue to recruit cholesterol to MAM, which helps explain the upregulation in MAM activity and ER-mitochondria connections found in cells from AD patients (22, 24) . In agreement with this idea, C99 CBD defective in cholesterol binding failed to promote the upregulation of MAM functionality.
This effect on the formation and activation of lipid raft domains has been shown for the sigma-1 receptor, a MAM-resident protein (45) that, via its capacity to bind cholesterol, it causes the remodeling of lipid rafts and the regulation of the signaling molecules that are present in them (46) .
Overall, we believe that our hypothesis suggests a potential mechanism to explain the seminal role of cholesterol in AD, underscored by the multiple genetic studies that have identified polymorphisms in genes related to cholesterol metabolism and the incidence of AD (47) .
Moreover, our data helps clarify the interdependence between cholesterol and APP metabolism (38) ; and the controversial association between cholesterol levels in AD (48) , which we believe that could be rooted in the fact that defects in neuronal transmission could be caused by alterations in the distribution of subcellular cholesterol, rather than overall changes in cholesterol concentration.
Taken together, we propose a model in which C99 accumulation and increased cholesterol uptake occurs early in the pathogenesis of AD. Such a model would help create a framework to understand the role of cholesterol as both cause and consequence in the pathogenesis of AD, and the participation of many genetic loci associated with lipid metabolism, and specifically cholesterol regulation, in the pathogenesis of AD. In addition, it supports the idea that the APP C-terminal fragment acts as a cholesterol sensor protein in the membrane (44) , whose cleavage regulate lipid homeostasis in the cell, coordinating the lipid composition of the PM and the intracellular lipid sensing platforms, namely MAM. Figure 6 . Schematic representation of the potential role of C99 in the regulation of cholesterol trafficking, and its relevance to AD. By means of its affinity for cholesterol, uncleaved C99 at the ER, induces the uptake and retrograde transport of cholesterol from the PM to the ER, resulting in the formation of a lipid raft domain, or MAM. These C99-dependent lipid-rafts would passively segregate and organize lipid-binding proteins, thereby facilitating their interaction and the regulation of specific signaling pathways. Failure to cleave C99 completely would result in a futile cycle of continuous uptake of extracellular cholesterol and its mobilization from the PM to ER, resulting in the upregulation of MAM formation and activation, which in turn would cause the upregulation of SMases, ACAT activity, and LD deposition. Closing the cycle, this accumulation of cholesterol in membranes also induces APP internalization and its interaction and cleavage by BACE1, and the downregulation of α-secretase activity
